Repository logo
 

An FGFR1-SPRY2 Signaling Axis Limits Basal Cell Proliferation in the Steady-State Airway Epithelium.

Published version
Peer-reviewed

Repository DOI


Change log

Authors

Balasooriya, Gayan I 
Johnson, Jo-Anne 
Basson, M Albert 
Rawlins, Emma L 

Abstract

The steady-state airway epithelium has a low rate of stem cell turnover but can nevertheless mount a rapid proliferative response following injury. This suggests a mechanism to restrain proliferation at steady state. One such mechanism has been identified in skeletal muscle in which pro-proliferative FGFR1 signaling is antagonized by SPRY1 to maintain satellite cell quiescence. Surprisingly, we found that deletion of Fgfr1 or Spry2 in basal cells of the adult mouse trachea caused an increase in steady-state proliferation. We show that in airway basal cells, SPRY2 is post-translationally modified in response to FGFR1 signaling. This allows SPRY2 to inhibit intracellular signaling downstream of other receptor tyrosine kinases and restrain basal cell proliferation. An FGFR1-SPRY2 signaling axis has previously been characterized in cell lines in vitro. We now demonstrate an in vivo biological function of this interaction and thus identify an active signaling mechanism that maintains quiescence in the airway epithelium.

Description

Keywords

Animals, Cell Proliferation, Cells, Cultured, Epithelial Cells, Epithelium, Female, Intracellular Signaling Peptides and Proteins, Male, Membrane Proteins, Mice, Mice, Inbred C57BL, Mice, Knockout, Protein Processing, Post-Translational, Protein Serine-Threonine Kinases, Receptor, Fibroblast Growth Factor, Type 1, Respiratory Mucosa, Signal Transduction, Trachea

Journal Title

Dev Cell

Conference Name

Journal ISSN

1534-5807
1878-1551

Volume Title

37

Publisher

Elsevier BV
Sponsorship
Medical Research Council (G0900424)
Wellcome Trust (105602/Z/14/Z)
Medical Research Council (MC_PC_12009)
Wellcome Trust (092096/Z/10/Z)
Wellcome Trust (092087/Z/10/Z)
Cancer Research Uk (None)
This study was supported by the Medical Research Council (G0900424 to ER); Wellcome Trust clinical PhD fellowship (JJ). Core grants: Gurdon Institute: Wellcome Trust (092096), Cancer Research UK (C6946/A14492); Stem Cell Initiative: Wellcome Trust/MRC.